Indoco Remedies Limited has informed the Exchange regarding a press release dated May 23, 2025, titled "Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP 200 mg".
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies has received final approval from the USFDA to market Allopurinol Tablets USP 200 mg in the US through its ANDA (Abbreviated New Drug Application). This is a generic version of Zyloprim 200 mg, originally marketed by Casper Pharma LLC, used to treat high uric acid levels and kidney stones. The product will be manufactured at the company's Goa facility. Indoco, with a turnover of US$180 million, already has multiple USFDA-approved facilities and global tie-ups with generic companies.
This approval strengthens Indoco's US generic portfolio and opens a new revenue stream from the US market. Positive for the stock, though the actual financial impact depends on market share captured against competition for this off-patent drug.